Knowledge Base

Resources & Guides

Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.

Showing articles tagged: #503a Clear filter

Educational Content

View all →
Showing 6 of 6 articles
No articles found matching your search. Try a different term or view all articles.

How to Evaluate Compounded Tirzepatide Vendors: A 2026 Framework

A methodology-first guide to evaluating compounded tirzepatide vendors. Learn the 503A vs 503B distinction, why a prescription is non-negotiable, how to read a Certificate of Analysis, and the five signals that separate legitimate sources.

Retatrutide Compounding Pharmacy: 503A vs 503B Reality

Patients searching for a retatrutide compounding pharmacy expect a licensed pharmacist with a white coat. The federal reality is sharper: neither 503A pharmacies nor 503B outsourcing facilities can legally produce retatrutide, because both pathways require the active ingredient to sit on an FDA-evaluated list, and retatrutide does not. This guide explains both frameworks in plain English, then traces what people actually receive when they buy from a site that calls itself a compounding pharmacy.

Compounded Semaglutide Ban: Full FDA Timeline (2026 Update)

A dated regulatory timeline of the compounded semaglutide ban, from the February 2025 shortage resolution through the April 30, 2026 FDA proposal to remove semaglutide from the 503B bulks list, plus a plain-language 503A vs 503B explainer and a patient action guide.

Compounded Tirzepatide: What You Need to Know (2026 Guide)

Compounded tirzepatide costs a fraction of Mounjaro or Zepbound — see our full <a href="/resources/tirzepatide-cost" style="color: #2563eb;">tirzepatide cost guide</a> but sits at the center of an ongoing legal battle between Eli Lilly, compounding pharmacies, and the FDA. This guide covers the regulatory landscape after the October 2024 shortage removal, how to source safely, dosing considerations, reconstitution, storage, and what the court rulings mean for availability.

Compounded Retatrutide: Legal Status, Risks & Alternatives

Unlike semaglutide and tirzepatide, compounded retatrutide is explicitly prohibited under federal law — there is no approved version, so the shortage exemption never applied. This guide explains the legal reality, what's actually in research-peptide vials, and what your real options are.

Compounded Semaglutide: Cost, Safety & How to Source (2026)

Compounded semaglutide costs a fraction of Ozempic or Wegovy but carries distinct risks. This guide covers the FDA regulatory landscape after the 2025 shortage resolution, how to source safely from legitimate pharmacies, dosing considerations, reconstitution, storage, and red flags to watch for.